Post-operative Nausea and Vomiting (PONV) Market

Post-operative Nausea and Vomiting (PONV) Market (Treatment: Serotonin Antagonists, Steroids, Dopamine Antagonists, NK-1 Receptor Antagonists, Non-pharmacologic Treatment, and Others) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Outlook 2031

  • The post-operative nausea and vomiting (PONV) market size stood at US$ 2.1 Bn in 2022
  • It is expected to increase at a CAGR of 7.4% from 2023 to 2031 and reach US$ 4.0 Bn by the end of 2031

Analyst Viewpoint

As per the World Health Organization (WHO), cancer accounts for more than 10 million fatalities every year. Cancer-related surgeries are reported to result in post-operative nausea and vomiting, which in turn is driving the post-operative nausea and vomiting (PONV) industry growth. Moreover, the number of patients affected by anemia is increasing at a considerable rate. The year 2021 alone witnessed 1.92 billion people suffering from anemia. Increase in susceptibility of anemic patients to post-operative complications is estimated to propel the post-operative nausea and vomiting treatment market value during the forecast period.

Rise in the number of surgeries as a treatment option, surge in government initiatives for spreading awareness, and increase in focus of major pharmaceutical companies on the development of novel treatment therapies are estimated to boost the post-operative nausea and vomiting (PONV) market size in the upcoming years.

Post Operative Nausea And Vomiting Market

Market Introduction

Post-operative nausea and vomiting, or PONV, is one of the most common complications following surgery, and affects up to 80% of high-risk patients. This high prevalence drives the demand for effective treatment methods and development of new drugs, such as steroids, serotonin antagonists, and dopamine antagonists, in order to provide more options to manage recovery phase vomiting and nausea.

PONV is associated with significant patient dissatisfaction. It is also associated with longer stays in post-operative care units, unanticipated hospital admission, and increased healthcare costs. Therefore, improving patient satisfaction and reducing these costs are key factors that are projected to drive the post-operative nausea and vomiting (PONV) market in 2023.

Government guidelines on the implementation of institutional protocols to manage after-surgery nausea and vomiting and stringent regulations on approval of propofol and infusions are expected to negatively impact the post-operative nausea and vomiting treatment market forecast in the near future.

Increase in Number of Surgeries Fueling Post-Operative Nausea and Vomiting (PONV) Market Growth

Increase in number of surgeries performed across the globe is boosting the incidence of PONV, which in turn is fueling the demand for effective treatments. Moreover, growth and development of healthcare infrastructure worldwide, particularly in emerging economies, is a significant factor augmenting the post-op nausea market.

Painkillers are generally prescribed to relieve pain post a surgery. However, when it comes to mastectomy or thoracotomy or any cancer surgery, the pain could be long-term. This post-operative pain syndrome comprises nausea and vomiting apart from shivering, swelling/redness around the wound, loss of appetite. These side-effects hamper patient experience and satisfaction, which in turn is expected to impact the post-operative nausea and vomiting (PONV) market scenario during the forecast period.

Surge in Rate of Post-Operative Complications Driving Post-Operative Nausea and Vomiting (PONV) Market Demand

Comorbidities such as renal, cardiac, pulmonary, neurological, or hepatic ailments are associated with a noticeable increase in post-operative complications. Those contracting perioperative hypoalbuminemia and anemia are at a higher risk of post-operative nausea and vomiting. Emergency surgery has higher repercussions in the form of myocardial infarction, pneumonia, major bleeding, and stroke with higher mortality.

Post-operative complications increase hospital stays for patients and could lead to further escalation is medical expenses in terms of extra treatment procedures. Furthermore, rise in aging population and increase in medical co-morbidities across the globe are expected to considerably increase the incidence of expensive postoperative complications. This, in turn, is projected to propel the demand for PONV treatment during the forecast period.

Regional Post-Operative Nausea and Vomiting (PONV) Market Outlook

Analysis of the research report on post-operative nausea and vomiting (PONV) market reveals that North America held a prominent market share due to rise in number of surgeries performed in the U.S. As per National Center for Biotechnology Information, 40-50 million surgeries are performed in the U.S. every year. Furthermore, one of the key global market trends witnessed in the region is the growing awareness among patients about post-surgery care are their willingness to pay more to avoid post-operative complications.

According to the National Center for Biotechnology Information, nearly 20 million patients in Europe undergo major surgeries every year. It further states that more than 90% of them are either nauseated or experience vomiting sensation after surgery. These factors are projected to propel Europe’s post-operative nausea and vomiting (PONV) industry share during the forecast period.

Analysis of Key Players

According to the latest post-operative nausea and vomiting (PONV) market insights, the global market is highly competitive, with significant participation from both domestic and international players. Furthermore, the global market report suggests a market entry strategy for new market entrants. It also provides data that is expected to help market players to consolidate their distribution channels and expand geographical reach. A few prominent players operating in the global market include Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, GlaxoSmithKline Corporation, and Merck and Co.

Key Developments

  • In April 2022, the US FDA granted a new drug product exclusivity to Evoke Pharma, Inc. for Gimoti (metoclopramide) nasal spray.
  • In February 2022, Barhemsys from Acacia Pharmaceutical received approval from the US FDA for intravenous formulation of amisulpride (Dopamine Antagonist) to treat post-operative nausea and vomiting in those who did not respond to treatment from different class.
  • In September 2020, Sandoz (a Novartis division) introduced generic ‘Fosaprepitant’ – an anti-emetic drug to prevent nausea and vomiting induced through chemotherapy.

Key players in the post-operative nausea and vomiting (PONV) market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Post-operative Nausea and Vomiting (PONV) Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 2.1 Bn
Market Forecast Value in 2031 US$ 4.0 Bn
Growth Rate (CAGR) 7.4%
Forecast Period 2023-2031
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Market Segmentation
  • Treatment Type
    • Serotonin Antagonists
    • Steroids
    • Dopamine Antagonists
    • NK-1 Receptor Antagonists
    • Non-pharmacologic Treatment
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies & Drug Stores
Companies Profiled
  • Acacia Pharma
  • F. Hoffmann-La Roche AG
  • Novartis AG
  • Ani Pharmaceuticals, Inc.
  • Camurus AB
  • Sanofi S.A.
  • Helsinn Holding S.A.
  • Eisai Corporation
  • GlaxoSmithKline Corporation
  • Merck and Co.
Scope for Customization Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the post-operative nausea and vomiting (PONV) market in 2022?

It was valued at US$ 2.1 Bn in 2022

How is the post-operative nausea and vomiting industry expected to grow during the forecast period?

It is projected to grow at a CAGR of 7.4% from 2023 to 2031

What are the key factors driving the demand for post-operative nausea and vomiting treatment?

Increase in number of surgeries and surge in rate of post-operative complications

Which PONV segment held largest share in 2022?

In terms of distribution channel, the hospital pharmacies segment held largest share in 2022

Which region is expected to dominate the PONV business?

North America is estimated to dominate in the next few years

Who are the key PONV drug manufacturers?

Acacia Pharma, F. Hoffmann-La Roche AG, Novartis AG, Ani Pharmaceuticals, Inc., Camurus AB, Sanofi S.A., Helsinn Holding S.A., Eisai Corporation, GlaxoSmithKline Corporation, and Merck and Co.

1. Executive Summary

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

4. Market Overview

    4.1. Market Segmentation

        4.1.1. Segment Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, 2022-2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. COVID-19 Pandemic Impact on Industry

6. Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type

    6.1. Introduction and Definitions

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Treatment Type, 2023–2031

        6.3.1. Serotonin Antagonists

        6.3.2. Steroids

        6.3.3. Dopamine Antagonists

        6.3.4. NK-1 Receptor Antagonists

        6.3.5. Non-pharmacologic Treatment

        6.3.6. Others

    6.4. Market Attractiveness, by Treatment Type

7. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction and Definitions

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Distribution Channel, 2023–2031

        7.3.1. Hospital Pharmacies

        7.3.2. Online Pharmacies

        7.3.3. Retail Pharmacies & Drug Stores

    7.4. Market Attractiveness, by Distribution Channel

8. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region, 2023–2031

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness, by Region

9. North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Treatment Type, 2023–2031

        9.2.1. Serotonin Antagonists

        9.2.2. Steroids

        9.2.3. Dopamine Antagonists

        9.2.4. NK-1 Receptor Antagonists

        9.2.5. Non-pharmacologic Treatment

        9.2.6. Others

    9.3. Market Value Forecast, by Distribution Channel, 2023–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Online Pharmacies

        9.3.3. Retail Pharmacies & Drug Stores

    9.4. Market Value Forecast, by Country, 2023–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Treatment Type

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment Type, 2023–2031

        10.2.1. Serotonin Antagonists

        10.2.2. Steroids

        10.2.3. Dopamine Antagonists

        10.2.4. NK-1 Receptor Antagonists

        10.2.5. Non-pharmacologic Treatment

        10.2.6. Others

    10.3. Market Value Forecast, by Distribution Channel, 2023–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Online Pharmacies

        10.3.3. Retail Pharmacies & Drug Stores

    10.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Treatment Type

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Type, 2023–2031

        11.2.1. Serotonin Antagonists

        11.2.2. Steroids

        11.2.3. Dopamine Antagonists

        11.2.4. NK-1 Receptor Antagonists

        11.2.5. Non-pharmacologic Treatment

        11.2.6. Others

    11.3. Market Value Forecast, by Distribution Channel, 2023–2031

        11.3.1. Hospital Pharmacies

        11.3.2. Online Pharmacies

        11.3.3. Retail Pharmacies & Drug Stores

    11.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Treatment Type

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Type, 2023–2031

        12.2.1. Serotonin Antagonists

        12.2.2. Steroids

        12.2.3. Dopamine Antagonists

        12.2.4. NK-1 Receptor Antagonists

        12.2.5. Non-pharmacologic Treatment

        12.2.6. Others

    12.3. Market Value Forecast, by Distribution Channel, 2023–2031

        12.3.1. Hospital Pharmacies

        12.3.2. Online Pharmacies

        12.3.3. Retail Pharmacies & Drug Stores

    12.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Treatment Type

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment Type, 2023–2031

        13.2.1. Serotonin Antagonists

        13.2.2. Steroids

        13.2.3. Dopamine Antagonists

        13.2.4. NK-1 Receptor Antagonists

        13.2.5. Non-pharmacologic Treatment

        13.2.6. Others

    13.3. Market Value Forecast, by Distribution Channel, 2023–2031

        13.3.1. Hospital Pharmacies

        13.3.2. Online Pharmacies

        13.3.3. Retail Pharmacies & Drug Stores

    13.4. Market Value Forecast, by Country/Sub-region, 2023–2031

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Treatment Type

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)

    14.2. Market Share Analysis, by Company (2022)

    14.3. Company Profiles

        14.3.1. Acacia Pharma

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Product Portfolio

            14.3.1.3. Financial Overview

            14.3.1.4. SWOT Analysis

            14.3.1.5. Strategic Overview

        14.3.2. F. Hoffmann-La Roche AG

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Product Portfolio

            14.3.2.3. Financial Overview

            14.3.2.4. SWOT Analysis

            14.3.2.5. Strategic Overview

        14.3.3. Novartis AG

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Product Portfolio

            14.3.3.3. Financial Overview

            14.3.3.4. SWOT Analysis

            14.3.3.5. Strategic Overview

        14.3.4. Ani Pharmaceuticals, Inc.

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Product Portfolio

            14.3.4.3. Financial Overview

            14.3.4.4. SWOT Analysis

            14.3.4.5. Strategic Overview

        14.3.5. Camurus AB

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Product Portfolio

            14.3.5.3. Financial Overview

            14.3.5.4. SWOT Analysis

            14.3.5.5. Strategic Overview

        14.3.6. Sanofi S.A.

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Product Portfolio

            14.3.6.3. Financial Overview

            14.3.6.4. SWOT Analysis

            14.3.6.5. Strategic Overview

        14.3.7. Helsinn Holding S.A.

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Product Portfolio

            14.3.7.3. Financial Overview

            14.3.7.4. SWOT Analysis

            14.3.7.5. Strategic Overview

        14.3.8. Eisai Corporation

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Product Portfolio

            14.3.8.3. Financial Overview

            14.3.8.4. SWOT Analysis

            14.3.8.5. Strategic Overview

        14.3.9. GlaxoSmithKline Corporation

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Product Portfolio

            14.3.9.3. Financial Overview

            14.3.9.4. SWOT Analysis

            14.3.9.5. Strategic Overview

        14.3.10. Merck and Co.

            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.10.2. Product Portfolio

            14.3.10.3. Financial Overview

            14.3.10.4. SWOT Analysis

            14.3.10.5. Strategic Overview

List of Tables

Table 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 02: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 03: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Region, 2023–2031

Table 04: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 05: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 06: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country, 2023–2031

Table 07: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 08: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 09: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 10: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 11: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 12: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 13: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 14: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 15: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

Table 16: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2031

Table 17: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2031

Table 18: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2031

List of Figures

Figure 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 02: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 03: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 04: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 05: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 06: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2022 and 2031

Figure 07: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region, 2023–2031

Figure 08: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 09: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 10: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 11: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 12: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 13: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country, 2022 and 2031

Figure 14: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country, 2023–2031

Figure 15: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 16: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 17: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 18: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 19: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 20: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 22: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 23: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 24: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 25: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 26: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 27: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 28: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 30: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 31: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 32: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 33: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 34: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 35: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 36: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023–2031

Figure 37: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031

Figure 38: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023–2031

Figure 39: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 40: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023–2031

Figure 41: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 42: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 43: Global Post-operative Nausea and Vomiting (PONV) Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved